Literature DB >> 7582515

Pharmacological activity of the C-terminal and N-terminal domains of secretory leukoprotease inhibitor in vitro.

K Masuda1, T Kamimura, K Watanabe, T Suga, M Kanesaki, A Takeuchi, A Imaizumi, Y Suzuki.   

Abstract

1. In order to characterize the physiological functions of the domain structure of secretory leukoprotease inhibitor (SLPI), the biological capacities of half-length SLPIs, (Ser1-Pro54)SLPI and (Asn55-Ala107)SLPI, were investigated and compared with those of full-length SLPI. 2. The activities of these inhibitors against several serine proteases were determined using synthetic chromogenic substrates. The inhibitory capacity of the C-terminal domain, (Asn55-Ala107)SLPI, was as strong as that of full-length SLPI against human neutrophil elastase (NE), cathepsin G and chymotrypsin. It possessed less trypsin inhibitory activity than intact SLPI. For the N-terminal domain of SLPI, (Ser1-Pro54)SLPI, no inhibitory activity could be detected against the serine proteases tested in this study. 3. The inhibitory activity of (Asn55-Ala107)SLPI against the proteolysis of the natural substrates elastin and collagen by NE was comparable with that of full-SLPI (elastin, IC50 = 907 +/- 31 nM for SLPI, 767 +/- 33 nM for (Asn55-Ala107)SLPI; collagen, IC50 = 862 +/- 36 nM for SLPI, 727 +/- 47 nM for (Asn55-Ala107)SLPI). 4. The binding affinities of full- and half-length SLPIs for heparin were measured by affinity column chromatography. Full-length SLPI showed high affinity for heparin while the binding capacities of both half-length SLPIs were lower. (Concentration of NaCl for elution, 0.45 M for SLPI, 0.24 M for (Ser1-Pro54)SLPI, 0.27 M for (Asn55-Ala107)SLPI). 5. The effects of full-SLPI and (Asn55-Ala107)SLPI on blood coagulation were measured using the activated partial thromboplastin time (APTT). Full-length SLPI prolonged clotting time dose dependently(1.25, 2.5 and 5.0 microM), whereas (Asn55-AlalO7)SLPI had no effect even at the highest concentration.6. In conclusion, the C-terminal domain of SLPI is a promising candidate for the treatment of inflammatory diseases in which participation of neutrophil proteases has been suggested.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7582515      PMCID: PMC1909019          DOI: 10.1111/j.1476-5381.1995.tb15892.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  35 in total

1.  A linear equation that describes the steady-state kinetics of enzymes and subcellular particles interacting with tightly bound inhibitors.

Authors:  P J Henderson
Journal:  Biochem J       Date:  1972-04       Impact factor: 3.857

2.  Secretion of mucus proteinase inhibitor and elafin by Clara cell and type II pneumocyte cell lines.

Authors:  J M Sallenave; A Silva; M E Marsden; A P Ryle
Journal:  Am J Respir Cell Mol Biol       Date:  1993-02       Impact factor: 6.914

3.  Characterization of the human factor VIII procoagulant protein with a heterologous precipitating antibody.

Authors:  C A Fulcher; T S Zimmerman
Journal:  Proc Natl Acad Sci U S A       Date:  1982-03       Impact factor: 11.205

4.  Degradation of fibronectin by human leukocyte elastase. Release of biologically active fragments.

Authors:  J A McDonald; D G Kelley
Journal:  J Biol Chem       Date:  1980-09-25       Impact factor: 5.157

5.  Specific cleavage of human type III collagen by human polymorphonuclear leukocyte elastase.

Authors:  C L Mainardi; D L Hasty; J M Seyer; A H Kang
Journal:  J Biol Chem       Date:  1980-12-25       Impact factor: 5.157

6.  Stimulation of the elastolytic activity of leukocyte elastase by leukocyte cathepsin G.

Authors:  C Boudier; C Holle; J G Bieth
Journal:  J Biol Chem       Date:  1981-10-25       Impact factor: 5.157

7.  Kinetics of association of serine proteinases with native and oxidized alpha-1-proteinase inhibitor and alpha-1-antichymotrypsin.

Authors:  K Beatty; J Bieth; J Travis
Journal:  J Biol Chem       Date:  1980-05-10       Impact factor: 5.157

8.  Synthesis of a gene for human growth hormone and its expression in Escherichia coli.

Authors:  M Ikehara; E Ohtsuka; T Tokunaga; Y Taniyama; S Iwai; K Kitano; S Miyamoto; T Ohgi; Y Sakuragawa; K Fujiyama
Journal:  Proc Natl Acad Sci U S A       Date:  1984-10       Impact factor: 11.205

9.  Emphysema and bronchial secretory cell metaplasia induced in hamsters by human neutrophil products.

Authors:  G L Snider; E C Lucey; T G Christensen; P J Stone; J D Calore; A Catanese; C Franzblau
Journal:  Am Rev Respir Dis       Date:  1984-01

10.  Localization of low molecular weight protease inhibitor in serous secretory cells of the respiratory tract.

Authors:  J A Kramps; C Franken; C J Meijer; J H Dijkman
Journal:  J Histochem Cytochem       Date:  1981-06       Impact factor: 2.479

View more
  5 in total

1.  Effects of secretory leucocyte protease inhibitor on the production of the anti-inflammatory cytokines, IL-10 and transforming growth factor-beta (TGF-beta), by lipopolysaccharide-stimulated macrophages.

Authors:  C Sano; T Shimizu; K Sato; H Kawauchi; H Tomioka
Journal:  Clin Exp Immunol       Date:  2000-07       Impact factor: 4.330

2.  Production of secretory leucocyte protease inhibitor (SLPI) in human pancreatic beta-cells.

Authors:  M Nyström; M Bergenfeldt; I Ljungcrantz; A Lindeheim; K Ohlsson
Journal:  Mediators Inflamm       Date:  1999       Impact factor: 4.711

3.  Secretory leukocyte protease inhibitor in punch biopsies from human colonic mucosa.

Authors:  M Nyström; U P Westin; C Linder; K Ohlsson
Journal:  Mediators Inflamm       Date:  2001-10       Impact factor: 4.711

4.  Structure basis 1/2SLPI and porcine pancreas trypsin interaction.

Authors:  Kei Fukushima; Takashi Kamimura; Midori Takimoto-Kamimura
Journal:  J Synchrotron Radiat       Date:  2013-09-29       Impact factor: 2.616

5.  Neutrophils and Activated Macrophages Control Mucosal Immunity by Proteolytic Cleavage of Antileukoproteinase.

Authors:  Jennifer Vandooren; Pieter Goeminne; Lise Boon; Estefania Ugarte-Berzal; Vasily Rybakin; Paul Proost; Ahmed M Abu El-Asrar; Ghislain Opdenakker
Journal:  Front Immunol       Date:  2018-05-28       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.